Nurix

SentiAR is a developer of a real-time, multi-modal holographic augmented reality platform for interventional cardiac procedures that enables electrophysiologists to visualize 3D cardiac anatomy and catheter data through a hands-free headset. The company's platform includes VistaMD, a virtual screen system available now that adds up to five customized virtual screens from up to eight simultaneous inputs including EGMs, ICE, fluoroscopy, and ablation parameters, anchored hands-free in the physician's field of view without requiring ceiling-mounted booms; and CommandEP, the world's first FDA-cleared mixed-reality platform for cardiac electrophysiology that converts real-time catheter data into a hands-free 3D hologram of the patient's anatomy with native EAMS integration expected in the first half of 2027. The PARADIGM Study, a prospective randomized multicenter crossover trial at Massachusetts General Hospital and Beth Israel Deaconess Medical Center involving 102 patients and 8 electrophysiologists, demonstrated 25% fewer missed targets, 92% fewer intraprocedural communications, and 94% physician comfort. Real-world utilization showed 98% first-pass isolation across 15 pulsed-field ablation cases. Built on Magic Leap 2 hardware, SentiAR is a Washington University in St. Louis spinout with two FDA 510(k) clearances and 30 patents filed. Founded in 2017 and headquartered in St. Louis, Missouri, SentiAR has raised $28.3 million in Series B funding from investors including NIH, Cultivation Capital, TechWald Holding, VCapital, Neue Fund, Keiretsu Forum, BioGenerator, and MedVenture Partners.